J. Rak

Publications101
h-index37
Citations8,395
Highly Influential Citations252
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • R. Kerbel
  • 549 Publications, 46,500 Citations
  • N. Mackman
  • 580 Publications, 38,039 Citations
  • X. Breakefield
  • 369 Publications, 30,559 Citations
  • N. Ferrara
  • 458 Publications, 121,517 Citations
  • Publications
  • Influence
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells
Aggressive human brain tumours (gliomas) often express a truncated and oncogenic form of the epidermal growth factor receptor, known as EGFRvIII. Within each tumour only a small percentage of glioma… Expand
  • 1,380
  • 74
  • PDF
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR
Activated EGF receptor (EGFR) plays an oncogenic role in several human malignancies. Although the intracellular effects of EGFR are well studied, its ability to induce and modulate tumor angiogenesis… Expand
  • 522
  • 29
  • PDF
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo:…
The overexpression in tumor cells of (proto)-oncogenic receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) or ErbB2/neu (also known as HER-2) is generally thought to contribute… Expand
  • 878
  • 19
CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity.
CD44 is expressed in various isoforms on numerous cell types and tissues during embryogenesis and in the mature organism. CD44 may also be involved in tumor growth. To study the multiple roles of… Expand
  • 391
  • 18
  • PDF
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
Various conventional chemotherapeutic drugs can block angiogenesis or even kill activated, dividing endothelial cells. Such effects may contribute to the antitumor efficacy of chemotherapy in vivo… Expand
  • 714
  • 16
  • PDF
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
Various conventional chemotherapeutic drugs can block angiogenesis or even kill activated, dividing endothelial cells. Such effects may contribute to the antitumor efficacy of chemotherapy in vivo… Expand
  • 545
  • 9
Microvesicles: Messengers and mediators of tumor progression
Cellular interactions play a crucial role in progression, angiogenesis and invasiveness of tumors, including glioma. The traditionally accepted view is that medium and long-range cellular… Expand
  • 358
  • 9
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Although standard anticancer chemotherapeutic drugs have been designed to inhibit the survival or growth of rapidly dividing tumor cells, it is possible to enhance the efficacy of such drugs by… Expand
  • 439
  • 7
  • PDF
Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells.
  • J. Tran, J. Rak, +4 authors R. Kerbel
  • Chemistry, Medicine
  • Biochemical and biophysical research…
  • 2 November 1999
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that has been shown to act as an endothelial cell mitogen as well as a vascular permeability factor. Several recent reports… Expand
  • 366
  • 7
The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells.
The production and local release of various proteolytic enzymes, either by tumor cells or tumor-associated stromal cells, is thought to facilitate the malignant behavior of solid tumors. Human… Expand
  • 105
  • 5
  • PDF